"glenmark-pharmaceuticals"

For the fiscal ended March this year, the company posted a net profit of Rs 970.1 crore as against Rs 776 crore in the previous fiscal, Glenmark said.

The company's product is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.